These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 29282521)

  • 1. Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells.
    Anticoli S; Aricò E; Arenaccio C; Manfredi F; Chiozzini C; Olivetta E; Ferrantelli F; Lattanzi L; D'Urso MT; Proietti E; Federico M
    J Mol Med (Berl); 2018 Feb; 96(2):211-221. PubMed ID: 29282521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation.
    Di Bonito P; Chiozzini C; Arenaccio C; Anticoli S; Manfredi F; Olivetta E; Ferrantelli F; Falcone E; Ruggieri A; Federico M
    Int J Nanomedicine; 2017; 12():4579-4591. PubMed ID: 28694699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors.
    Ferrantelli F; Manfredi F; Chiozzini C; Anticoli S; Olivetta E; Arenaccio C; Federico M
    Mol Biotechnol; 2018 Nov; 60(11):773-782. PubMed ID: 30167966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
    Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Exosome-Based Vaccine Platform Imparts Cytotoxic T Lymphocyte Immunity Against Viral Antigens.
    Anticoli S; Manfredi F; Chiozzini C; Arenaccio C; Olivetta E; Ferrantelli F; Capocefalo A; Falcone E; Ruggieri A; Federico M
    Biotechnol J; 2018 Apr; 13(4):e1700443. PubMed ID: 29274250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
    Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
    BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
    Ko HJ; Kim YJ; Kim YS; Chang WS; Ko SY; Chang SY; Sakaguchi S; Kang CY
    Cancer Res; 2007 Aug; 67(15):7477-86. PubMed ID: 17671218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a cancer vaccine: peptides, proteins, and DNA.
    Shiku H; Wang L; Ikuta Y; Okugawa T; Schmitt M; Gu X; Akiyoshi K; Sunamoto J; Nakamura H
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S77-82. PubMed ID: 10950153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes.
    Di Bonito P; Accardi L; Galati L; Ferrantelli F; Federico M
    Cancers (Basel); 2019 Jan; 11(2):. PubMed ID: 30682811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.
    Chiozzini C; Olivetta E; Sanchez M; Arenaccio C; Ferrantelli F; Leone P; Federico M
    J Mol Med (Berl); 2019 Aug; 97(8):1139-1153. PubMed ID: 31161312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.
    zum Büschenfelde CM; Metzger J; Hermann C; Nicklisch N; Peschel C; Bernhard H
    J Immunol; 2001 Aug; 167(3):1712-9. PubMed ID: 11466395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
    Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
    Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
    Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
    Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
    Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced suppression of polyclonal CD8
    Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
    J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer.
    Yu Y; Pilgrim P; Zhou W; Gagliano N; Frezza EE; Jenkins M; Weidanz JA; Lustgarten J; Cannon M; Bumm K; Cobos E; Kast WM; Chiriva-Internati M
    Viral Immunol; 2008 Dec; 21(4):435-42. PubMed ID: 19115932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice.
    Cao J; Jin Y; Li W; Zhang B; He Y; Liu H; Xia N; Wei H; Yan J
    BMC Immunol; 2013 Aug; 14():39. PubMed ID: 23941509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.